NEW YORK (GenomeWeb) – The Centers for Medicare and Medicaid Services on Thursday published a draft local coverage determination (LCD) for GenomeDx's Decipher genomic test for men who have undergone a radical prostatectomy.

The determination relates to Medicare coverage for the test. A 45-day comment period will begin on Nov. 10 and the final LCD will be posted within 45 days after comments are received and any revisions to the proposal are made. Medicare administrator Palmetto GBA issued the draft LCD for Decipher through the MolDX Program.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.